Akums Drugs and Pharmaceuticals to host InsightX 2026 virtual meet
Akums Drugs and Pharmaceuticals Limited has announced an investor and analysts meet scheduled for June 12, 2026, as part of the InsightX 2026 Virtual Conference. The virtual group meet will begin at 12:00 noon IST, with no unpublished price sensitive information to be shared. The disclosure complies with SEBI regulations and has been signed by Company Secretary Dharamvir Malik.

*this image is generated using AI for illustrative purposes only.
Akums Drugs and Pharmaceuticals Limited has scheduled an investor and analysts meet as part of the InsightX 2026 Virtual Conference. The meeting is set to take place on June 12, 2026, commencing at 12:00 noon IST. This interaction provides a platform for the company to engage with the investor community, though no unpublished price sensitive information will be disclosed during the session.
The event is classified as a group meet and will be conducted virtually. The schedule is subject to change due to exigencies on the part of the host or the company. The disclosure was made in compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
| S. No. | Particulars of Meet | Date of Meeting | Type of Meet | Location / Mode of Meeting |
|---|---|---|---|---|
| 1. | InsightX 2026 Virtual Conference | June 12, 2026 Starts at 12:00 noon (IST) |
Group meet | Virtual |
Dharamvir Malik, Company Secretary & Compliance Officer, signed the disclosure on behalf of Akums Drugs and Pharmaceuticals Limited. A copy of the intimation has been updated on the company's official website.
Historical Stock Returns for Akums Drugs & Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.53% | +4.50% | -1.59% | +31.05% | -3.53% | -31.15% |
What strategic growth initiatives does Akums Drugs plan to highlight for the 2026 fiscal year?
How might the company's pipeline expansions impact its competitive positioning in the pharmaceutical sector?
What are the expected market trends in the industry that Akums aims to leverage during this period?


































